Renal failureand Quality of Life Indicatorsin Kidney Transplantation

1. Abstract Health-related quality of life (HRQL) contains many aspects of patients'healthsuchasphysical,psychological,socialfunctioning andageneralwell-being.Progressinrenaltransplantationandimmunosuppressive therapies have increased significantly in recent decades, resulting in allograft survival rates at one year is now over 90%. Numerous clinical trials have established the importance of quality of life in a variety of diseases, and it is extremely populartoevaluatequalityoflifeinclinicaltrialsasameasureof patients' subjective state of health. The purpose of the study was to identify factors associated with quality of life after renal transplantation.

2. Introduction Kidneytransplantationisthetreatmentofchoiceinendstagerenal failure. The transplantation may be the focus for increasing survival and to maximize quality of life. However, there are certain factorsthatmayaffectthequalityoflifeaftertransplantation,such assideeffectsfromhighlyimmunosuppressivedrugs,thepresence ofcommondiseasestatesandthepossibilityofrejection.Themain goaloftransplantationistoachievemaximumqualityandlongev- ity while minimizing the impact of disease and health care costs. HRQLisalsoprogressivelybeingrecognizedasanimportantoutcome measure after organ transplantation.Along with other indicators related to patient improvement and graft survival, qualityoflifehasbeenassessedasavalidoutcomemeasure.Researcho n quality of life aims to lead to a broader view of subjective health, astheyconsiderhealthtobeapuzzleofgeneralwell-being.It is generally accepted that patients with a functional kidney transplanthaveanimprovedqualityoflifecomparedtopatientsundergoingdialysis.Specifictoolsinassessingthequalityoflifein kidney transplant are: the kidney transplant questionnaire (KTQ), the quality of life in kidney disease (KDQOL), and the transplant unit's end-stage renal disease (ESRDSC-TM) checklist. The ESRDSC-TM was developed specifically to evaluate the effects of immunosuppressivedrugsonqualityoflife.Theauthorsscreened more than 400 transplant patients and evaluated the re-screening correlation in a subset of 88 patients over a one-year period and found sufficient validity. General tools are used for comparisons between groups and studies and to assess the impact of different diseasesonqualityoflife(QOL).Thesetoolsareusedinresearch and are as follows: Sickness Impact Profile (SIP), the 36-item modifiedmedicalOutcomesSurvey(SF-36),andtheNottingham HealthProfile(NHP).Withmorethan200publications,theSF-36 is one of the most widely used tools for assessing quality of life [1- 16].

3. Results ThereisevidencefortheuseoftheSF-36inpatientswithchronic renalfailure.TheEQ-5Disfavoredamongthepreferredmeasurements, as there is more evidence, but this ratio applicable to the above. Since multidimensional specific renal disease measurements in KDQOLincludes most evidence. Given this overlap betweentheSF-36andKDQOL,thereissomebenefitwhenusedin the same survey, unlike the combination of EQ-5D and KDQOL provides additional information about the perception of patients for kidney disease. While the idea of using a short questionnaire basedonseveritywouldbeverygood,themainbenefitwouldonly controlorrecognitionofsymptoms.TheSF-36istheonlygeneral measurement with good properties and functional characteristics. Further more psychometric criteria can be reproduced when administeredasautonomousaspossible, andwhenusedinconjunc-tion with KDQOL questionnaire. The EQ-5D appears to have a favorable use, since three of the four studies that used the EQ-5D wereconductedintheUK.Theevidenceshowhighresponserates.

4. Conclusion Ingeneral,qualityoflifeimprovedafterasuccessfulkidneytransplant compared with dialysis patients, and the effect was more pronounced in men than in women. These studies clearly show that kidney transplantation is not only the cheapest long-term replacementtherapy,butisalsoassociatedwithlowermortalityand better quality of life for patients.

References 1. BassEB,WillsS,FinkNE.Howstrongarepatients’preferencesinchoice s between dialysis modalities and doses? Am J Kidney Dis.2004; 44: 695-705.

2. WasserfallenJB,HalabiG,SaudanP.Qualityoflifeonchronicdi-alysis: comparison between haemodialysis and peritoneal dialysis.Nephrol Dial Transplant. 2004; 19: 1594-9

3. ForsbergA, Lorenzon U, Nilsson F, Backmana L. Pain and healthrelated quality of life after heart, kidney, and liver transplantation.Clin Transplant 1999;13: 453-60.

4. Hays RD, Kallich JD, Mapes DL. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res. 1994; 3:329-38.

5. CanadianErythropoietinStudyGroup.Associationbetweenrecombinanthumanerythropoietinandqualityoflifeandexercisecapaci-ty of patients receiving haemodialysis. BMJ 1990; 300: 573-8

6. Churchill DN, Wallace JE, Ludwin D.Acomparison of evaluativeindicesofqualityoflifeandcognitivefunctioninhemodialysi spa-tients. Control Clin Trials 1991; 12(Suppl.): S159-67.

7. Harris DC, Chapman JR, Stewart JH. Low dose erythropoietin inmaintenance haemodialysis: improvement in quality of life and re-duction in true cost of haemodialysis. Aust N Z J Med. 1991; 21:693-700.

8. LaupacisA,KeownP,PusN.Astudyofthequalityoflifeand cost-utility of renal transplantation. Kidney Int 1996; 50: 235-42.

9. Sesso R, Yoshihiro MM,Ajzen H. Late diagnosis of chronic renalfailure and the quality of life during dialysis treatment. Braz J MedBiol Res. 1996; 29: 1283-9.

10. Sesso R,Yoshihiro MM.Time of diagnosis of chronic renal failureandassessmentofqualityoflifeinhaemodialysispatients.Nephr olDial Transplant. 1997; 12: 2111-6.

11. CleemputI,KestelootK,DeGeestS.Healthprofessionals’percep-tions of health status after renal transplantation: a comparison withtransplantationcandidates’expectations.Transplantation.2003;7 6: 176-82.

12. GreinerW,ObermannK,Grafvd.SchulenburgJ-M.Socioeconomicevaluationofkidney-transplantationinGermany.ArchHellMed. 2001; 18: 147-55.

13. MoonsP,VanrenterghemY,VanHooffJP.Healthrelatedqualityof lifeandsymptomexperienceintacrolimus-basedregimensafter renaltransplantation:amulticentrestudy.TransplInt.2003;16:653- 64.

14. PolskyD,WeinfurtKP,KaplanB.Aneconomicandquality-oflifeassessment of basiliximab vs antithymocyte globulin immunoprphylaxisinrenaltransplantation.NephrolDialTransplant.2001;16:102 8-33.

15. Roderick P, Nicholson T, Armitage A. An evaluation of the costs,effectiveness and quality of renal replacement therapy provision inrenal satellite units in England and Wales. Health TechnolAssess.2005; 9: 1-178.

16. McFarlane PA, Bayoumi AM, Pierratos A, Redelmeier DA. Thequality of life and cost utility of home nocturnal and conventionalincenter hemodialysis. Kidney Int. 2003; 64: 1004-11

Maria Dalamagka. Renal failureand Quality of Life Indicatorsin Kidney Transplantation. Annals of Clinical and Medical Case Reports 2022